Compare EIG & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | PCRX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.9M | 1.0B |
| IPO Year | 2007 | 2011 |
| Metric | EIG | PCRX |
|---|---|---|
| Price | $43.66 | $19.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.33 |
| AVG Volume (30 Days) | 285.6K | ★ 1.0M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.58 | 0.47 |
| Revenue | ★ $904,800,000.00 | $716,791,000.00 |
| Revenue This Year | $3.75 | $6.21 |
| Revenue Next Year | N/A | $8.26 |
| P/E Ratio | ★ $16.87 | $42.12 |
| Revenue Growth | 1.69 | ★ 3.14 |
| 52 Week Low | $35.73 | $18.80 |
| 52 Week High | $52.29 | $27.64 |
| Indicator | EIG | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 32.96 |
| Support Level | $43.01 | $18.80 |
| Resistance Level | $45.99 | $21.12 |
| Average True Range (ATR) | 0.94 | 1.19 |
| MACD | -0.24 | -0.25 |
| Stochastic Oscillator | 23.99 | 12.91 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.